Please assess the completion status of the following clinical trial:

Trial Title: Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed invasive breast cancer, meeting 1 of the following criteria:~  * SBR grade I-II disease (patients \< 65 years of age)~ * SBR grade I-III disease (patients \> 65 years of age)~* T2 (2-5 cm), T3, or T4B, and N0-1 disease~* No metastatic disease~* Breast lesion not amenable to breast-conserving resection~* No inflammatory breast cancer~* No prior breast cancer~* Hormone receptor status:~  * Estrogen receptor- and/or progesterone receptor-positive~PATIENT CHARACTERISTICS:~* Postmenopausal~* No other cancer within the past 5 years except for adequately treated skin carcinoma or carcinoma in situ of the cervix~* No contraindication to anti-hormonal treatment~* No psychological, familial, social, or geographical reasons that would preclude follow up~PRIOR CONCURRENT THERAPY:~* At least 8 days since prior hormone replacement therapy~* No concurrent anti-vitamin K treatment

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (ANA) (Type: ACTIVE_COMPARATOR): Patients receive oral anastrozole as 1 mg film-coated tablets, once daily for 6 months.
- Arm B (FULV) (Type: EXPERIMENTAL): Patients receive fulvestrant intramuscularly ( 250 mg/5 ml solution) on days 1, 14, and 28 and then once a month thereafter until 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).